Mona Lisa Touch Clinical Outcomes Registry
Long-term Outcomes Following Mona Lisa Touch Fractional CO₂ Laser Treatment for Genitourinary Syndrome of Menopause: an Ongoing Observational Cohort Study
Genitourinary syndrome of menopause is a common condition that can affect women after the menopause. It may cause vaginal dryness, soreness, pain during sex, urinary symptoms and a reduced quality of life. Standard treatments include vaginal moisturisers, lubricants and vaginal oestrogen. Some women do not respond fully to these treatments, cannot use oestrogen, or prefer an alternative option.
This study will look at outcomes following treatment with MonaLisa Touch, a fractional carbon dioxide laser treatment. "Fractional carbon dioxide laser" means that a medical laser is used to deliver small, controlled areas of heat to the vaginal tissue. The aim is to stimulate healing and improve symptoms. This study will not test a new treatment or change the patient's usual care. It will observe patients who are already receiving MonaLisa Touch treatment as part of routine clinical practice.
The main question is whether patients report improvement in their symptoms and quality of life after treatment, and whether any side effects or complications occur. The study will also help doctors and patients better understand longer-term outcomes following treatment.
Participants will be women with symptoms of genitourinary syndrome of menopause who are being considered for, or are receiving, MonaLisa Touch treatment. Participation will involve giving consent for information about their symptoms, treatment and follow-up to be collected and analysed. This may include questionnaires before and after treatment. Taking part is voluntary and will not affect the care offered.
The study will be conducted in a private clinical setting at Clarendon Health. It is expected to run as an ongoing observational study, with participants followed up after treatment as part of routine care.
The research is funded by Clarendon Health and no personal identifying information will be included in published results.
Обзор исследования
Статус
Статус
Условия
Условия
Вмешательство/лечение
Вмешательство/лечение
Тип исследования
Тип исследования
Регистрация (Оцененный)
Регистрация
Контакты и местонахождение
Контакты исследования
Контакты исследования
- Имя: Alexander Taylor
- Номер телефона: +44 (0)1202 026073
- Электронная почта: alextaylor@clarendonhealth.co.uk
Критерии участия
Критерии приемлемости
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Метод выборки
Исследуемая популяция
Women with symptoms consistent with genitourinary syndrome of menopause. These may include vaginal dryness, soreness, irritation, pain during sex, urinary symptoms, recurrent urinary symptoms, or related symptoms affecting quality of life.
Описание
Inclusion Criteria:
Women aged 35 years or over.
Women with symptoms consistent with genitourinary syndrome of menopause (GSM), including vaginal dryness, soreness, irritation, pain during sexual intercourse, urinary symptoms, or related symptoms affecting quality of life.
Women who are perimenopausal or postmenopausal, or who have menopause-related symptoms associated with premature ovarian insufficiency, early menopause, surgical menopause, medically induced menopause, or treatment-related oestrogen deficiency.
Women with menopause-related symptoms following breast cancer or other cancer treatments, including those receiving oestrogen-blocking treatments such as aromatase inhibitors or tamoxifen, may be included where clinically appropriate.
Women who are being considered for, or are receiving, MonaLisa Touch fractional carbon dioxide laser treatment as part of routine clinical care.
Women who are able to understand the study information and provide informed consent.
Women who are willing for relevant clinical information, treatment details, follow-up information and outcomes to be collected and analysed for research purposes.
Women who are willing to complete patient-reported outcome questionnaires before and after treatment, where applicable.
Women who agree to the review of relevant clinical records, including treatment details, additional therapies, follow-up findings and reported adverse events.
Exclusion Criteria:
- Women under 35 years of age.
Women without symptoms consistent with genitourinary syndrome of menopause or menopause-related oestrogen deficiency.
Women considered unsuitable for MonaLisa Touch fractional carbon dioxide laser treatment following clinical assessment.
Women with active or suspected genital, vaginal, urinary or pelvic infection requiring investigation or treatment before laser therapy.
Women with unexplained vaginal bleeding that has not been appropriately investigated.
Women with suspected or confirmed gynaecological malignancy requiring further investigation or treatment before laser therapy.
Women who are pregnant.
Women who are unable to understand the study information or provide informed consent.
Women who do not consent to the use of their clinical information or patient-reported outcomes for research purposes.
Women who are unable or unwilling to complete the required study questionnaires or follow-up assessments.
Women for whom the treating clinician considers study participation inappropriate because of clinical risks, safeguarding concerns or other relevant circumstances
Учебный план
Как устроено исследование?
Детали дизайна
- Наблюдательные модели: COHORT
- Временные перспективы: PROSPECTIVE
Что измеряет исследование?
Первичные показатели результатов
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Change in overall GSM symptom severity using a predefined composite 0-10 score
Временное ограничение: 4 years
|
Overall genitourinary syndrome of menopause (GSM) symptom severity will be assessed using a study-specific, non-validated numerical rating scale covering five symptom domains: vaginal dryness, burning or soreness, itching or irritation, pain during intercourse, and urinary symptom severity. Each domain is scored from 0 (no symptoms) to 10 (worst imaginable symptoms). The composite score is the mean of the applicable domain scores, ranging from 0 to 10, with higher scores indicating worse symptoms. At least four domains must have valid baseline and follow-up scores. The same domains will be used at both assessments. Non-applicable or missing responses are excluded; no values will be imputed. Change is calculated as follow-up minus baseline composite score. Negative values indicate improvement. |
4 years
|
Вторичные показатели результатов
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Change in Vaginal Health Index (VHI)
Временное ограничение: 4 years
|
Vaginal health will be assessed using the Vaginal Health Index (VHI), a clinician-assessed measure evaluating five parameters: vaginal elasticity, vaginal fluid volume, vaginal pH, epithelial integrity and vaginal moisture. Each parameter is scored from 1 to 5, producing a total score ranging from 5 to 25. Higher scores indicate better vaginal health. The change in VHI score will be calculated by subtracting the baseline score from the follow-up score. Positive values indicate improvement in vaginal health, while negative values indicate deterioration. VHI scores will be compared before and after MonaLisa Touch fractional carbon dioxide laser treatment to assess changes in vaginal tissue health over time. |
4 years
|
|
How do outcomes vary between patients, including those who use MonaLisa Touch treatment alone and those who also use other treatments, such as vaginal oestrogen?
Временное ограничение: 4 years
|
Changes in overall genitourinary syndrome of menopause (GSM) symptom severity will be compared between participants receiving MonaLisa Touch fractional carbon dioxide laser treatment alone and those receiving MonaLisa Touch alongside additional treatments, such as vaginal oestrogen. Symptom severity will be assessed using the study-specific composite numerical rating scale, ranging from 0 (no symptoms) to 10 (worst imaginable symptoms), as defined in the primary outcome measure. For each participant, change in symptom severity will be calculated by subtracting the baseline composite score from the follow-up score. The mean change in each treatment group will then be calculated, and the difference in mean change between groups will be reported. Negative changes indicate symptom improvement. This comparison will be exploratory, as treatment allocation is not randomised and differences between groups may be influenced by patient characteristics and other treatments. |
4 years
|
|
Change in Female Sexual Function Index (FSFI)
Временное ограничение: 4 years
|
Sexual function will be assessed using the validated 19-item Female Sexual Function Index (FSFI), a patient-reported questionnaire evaluating six domains: sexual desire, arousal, lubrication, orgasm, satisfaction and pain. Domain scores are calculated using the standard FSFI scoring method and combined to produce a total score ranging from 2 to 36, with higher scores indicating better sexual function. Change in sexual function will be calculated by subtracting the baseline FSFI total score from the follow-up score. Positive values indicate improvement in sexual function, while negative values indicate deterioration. FSFI scores will be assessed before and after MonaLisa Touch fractional carbon dioxide laser treatment to evaluate changes in sexual function over time. Results will be interpreted with consideration of participants' sexual activity status. |
4 years
|
|
Number of participants experiencing adverse events or complications
Временное ограничение: 4 years
|
The number of participants experiencing one or more adverse events, side effects or complications following MonaLisa Touch fractional carbon dioxide laser treatment will be recorded throughout the study follow-up period. Adverse events may include vaginal discomfort, pain, bleeding, discharge, infection, urinary symptoms or other unexpected effects reported following treatment. Events will be recorded according to their nature, severity, duration, outcome and possible relationship to treatment. Serious adverse events will be identified and documented separately. The number and percentage of participants experiencing at least one adverse event will be reported, together with a summary of the types and severity of events observed. |
4 years
|
Соавторы и исследователи
Спонсор
Спонсор
Публикации и полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования (Оцененный)
Начало исследования
Первичное завершение (Оцененный)
Первичное завершение
Завершение исследования (Оцененный)
Завершение исследования
Даты регистрации исследования
Первый отправленный
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Первый опубликованный
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее опубликованное обновление
Последнее отправленное обновление, отвечающее критериям контроля качества
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Другие идентификационные номера исследования
Другие идентификационные номера исследования
- CH-MLT-GSM-OBS-001
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .